Volume 23 Issue 6
Jun.  2025
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2025  >  23(6): 930-932
LIU Yang, ZHAO Lun, CHEN Yufo, ZHANG Shanshan, WU Yue, SHI Mengting, WANG Rui. Clinical observation of PD-1/PD-L1 inhibitor combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer[J]. Chinese Journal of General Practice, 2025, 23(6): 930-932. doi: 10.16766/j.cnki.issn.1674-4152.004035
Citation: LIU Yang, ZHAO Lun, CHEN Yufo, ZHANG Shanshan, WU Yue, SHI Mengting, WANG Rui. Clinical observation of PD-1/PD-L1 inhibitor combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer[J]. Chinese Journal of General Practice, 2025, 23(6): 930-932. doi: 10.16766/j.cnki.issn.1674-4152.004035
shu

Clinical observation of PD-1/PD-L1 inhibitor combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer

doi: 10.16766/j.cnki.issn.1674-4152.004035

  • Department of Medical Oncology, the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China

Funds:

 2023AH052000

 2022byzd042

  • Received Date: 2024-11-11
    Available Online: 2025-09-04
    Abstract
  •   Objective  To investigate the clinical value of programmed death receptor-1 (PD-1)/programmed death ligand-1 (PD-L1) immune checkpoint inhibitor combined with standard chemotherapy in the initial treatment of extensive small cell lung cancer (ES-SCLC), so as to comprehensively verify the clinical benefits and risk characteristics of the combined scheme.  Methods  The newly diagnosed ES-SCLC patients in the First Affiliated Hospital of Bengbu Medical University from January 2021 to June 2023 were analyzed retrospectively. According to different treatment schemes, 32 cases were divided into control group (etoposide+cisplatin/carboplatin) and 28 cases were divided into experimental group (PD-1/PD-L1 inhibitor+etoposide+cisplatin/carboplatin). The clinical therapeutic effect, tumor markers and adverse drug reactions of the two groups were compared.  Results  The objective remission rate [71.43% (20/28) vs. 53.13% (17/32), χ2=2.116, P=0.146] and disease control rate [89.29% (25/28) vs. 75.00% (24/32), χ2=2.036, P=0.154] in the experimental group were significantly higher than those in the control group, but the difference was not statistically significant. By the time of follow-up, the median overall survival (OS) of the experimental group was 4.2 months longer than that of the control group (14.0 months vs. 9.8 months, P=0.002). The median progression-free survival (PFS) in the experimental group was 1.1 months longer than that in the control group (5.6 months vs. 4.5 months, P=0.022). After treatment, there were statistically significant differences in the precursor of gastrin-releasing peptide [(88.55±13.48) pg/mL vs. (105.17±25.64) pg/mL] and neuron specific enolase [(38.85±13.94) ng/mL vs. (48.65±12.71) ng/mL] between the two groups (P < 0.05). There was no statistically significant difference in the incidence of grade 3 and above adverse events between the two groups [46.43% (13/28) vs. 43.75% (14/32), χ2=0.043, P=0.835].  Conclusion  PD-1/PD-L1 inhibitor combined with standard chemotherapy regimen is effective in the first-line treatment of ES-SCLC, which can effectively reduce the level of tumor markers and improve the survival prognosis of patients with good safety.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
    [2]
    REDDY H G, QIN A, KALEMKERIAN G P. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors[J]. Expert Opin Emerg Drugs, 2020, 25(3): 353-366. doi: 10.1080/14728214.2020.1798929
    [3]
    ORTEGA-FRANCO A, ACKERMANN C, PAZ-ARES L, et al. First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions[J]. ESMO Open, 2021, 6(1): 100003. DOI: 10.1016/j.esmoop.2020.100003.
    [4]
    RUI R, ZHOU L Q, HE S M. Cancer immunotherapies: advances and bottlenecks[J]. Front Immunol, 2023, 14: 1212476. DOI: 10.3389/fimmu.2023.1212476.
    [5]
    谷俊杰, 李彩莉, 代杰, 等. 79例食管恶性黑色素瘤的免疫治疗疗效及预后影响因素[J]. 中国肿瘤生物治疗杂志, 2023, 30(7): 612-615.

    GU J J, LI C L, DAI J, et al. Immunotherapy efficacy in 79 patients with malignant esophageal melanoma and the prognostic factors[J]. Chin J Cancer Biother, 2023, 30(7): 612-615.
    [6]
    DUBROT J, DU P P, LANE-RETICKER S K, et al. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer[J]. Nat Immunol, 2022, 23(10): 1495-1506. doi: 10.1038/s41590-022-01315-x
    [7]
    HUANG J T, ZHONG B Y, JIANG N, et al. Transarterial chemoembolization combined with immune checkpoint inhibitors plus tyrosine kinase inhibitors versus immune checkpoint inhibitors plus tyrosine kinase inhibitors for advanced hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2022, 9: 1217-1228. doi: 10.2147/JHC.S386672
    [8]
    LI Y, JI Y Y, SHEN L, et al. Clinical efficacy of combination therapy of an immune checkpoint inhibitor with taxane plus platinum versus an immune checkpoint inhibitor with fluorouracil plus platinum in the first-line treatment of patients with locally advanced, metastatic, or recurrent esophageal squamous cell carcinoma[J]. Front Oncol, 2022, 12: 1015302. DOI: 10.3389/fonc.2022.1015302.
    [9]
    刘佳, 王坚, 顾小伟, 等. 大分割放疗联合免疫检查点抑制剂治疗晚期转移性实体瘤的临床疗效研究[J]. 实用临床医药杂志, 2024, 28(6): 19-23.

    LIU J, WANG J, GU X W, et al. Clinical efficacy of hypofractionated radiotherapy combined with immune checkpoint inhibitors in treating advanced metastatic solid tumors[J]. Journal of Clinical Medicine in Practice, 2024, 28(6): 19-23.
    [10]
    蔡凌翼, 陈涛, 张晓琳, 等. 基于基因组学视角的乳腺癌化疗耐药机制研究进展[J]. 中华全科医学, 2023, 21(12): 2005-2008, 2073. doi: 10.16766/j.cnki.issn.1674-4152.003277

    CAI L Y, CHEN T, ZHANG X L, et al. Advances in the study of chemotherapy resistance mechanisms in breast cancer based on genomics perspective[J]. Chinese Journal of General Practice, 2023, 21(12): 2005-2008, 2073. doi: 10.16766/j.cnki.issn.1674-4152.003277
    [11]
    刘威, 张逸寅, 赵芳, 等. PD-1抑制剂联合抗血管生成药物治疗晚期肝细胞癌的疗效及预后影响因素分析[J]. 中华全科医学, 2024, 22(1): 64-69. doi: 10.16766/j.cnki.issn.1674-4152.003332

    LIU W, ZHANG Y Y, ZHAO F, et al. The efficacy and prognostic markers of anti-PD-1 immunotherapy combined with anti-angiogenic therapy for advanced hepatocellular carcinoma[J]. Chinese Journal of General Practice, 2024, 22(1): 64-69. doi: 10.16766/j.cnki.issn.1674-4152.003332
    [12]
    ZHANG S, CHENG Y. Immunotherapy for extensive-stage small-cell lung cancer: current landscape and future perspectives[J]. Front Oncol, 2023, 13: 1142081. DOI: 10.3389/fonc.2023.1142081.
    [13]
    LIU S V, RECK M, MANSFIELD A S, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)[J]. J Clin Oncol, 2021, 39(6): 619-630. doi: 10.1200/JCO.20.01055
    [14]
    WANG J, ZHOU C C, YAO W X, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2022, 23(6): 739-747. doi: 10.1016/S1470-2045(22)00224-8
    [15]
    ZHU Y W, LIU K, ZHU H, et al. Comparative efficacy and safety of novel immuno-chemotherapy for extensive-stage small-cell lung cancer: a network meta-analysis of randomized controlled trial[J]. Ther Adv Med Oncol, 2023, 15: 17588359231206147. DOI: 10.1177/17588359231206147.
    [16]
    CHENG Y, HAN L, WU L, et al. Effect of first-line Serplulimab vs. Placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial[J]. JAMA, 2022, 328(12): 1223-1232. doi: 10.1001/jama.2022.16464
    [17]
    CHENG Y, FAN Y, ZHAO Y Q, et al. Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage SCLC (RATIONALE-312): a multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial[J]. J Thorac Oncol, 2024, 19(7): 1073-1085. doi: 10.1016/j.jtho.2024.03.008
    [18]
    YU J, ZHOU C, WANG L, et al. P1.13A. 08 biomarker analysis of camrelizumab plus nab-paclitaxel and carboplatin as first-line treatment for extensive-stage small-cell lung cancer[J]. J Thorac Oncol, 2024, 19(10): S209-S210.
    [19]
    李建军, 张军峰, 牛红卫. 卡瑞利珠单抗联合替吉奥胶囊对晚期食管鳞癌的疗效及安全性研究[J]. 实用临床医药杂志, 2024, 28(12): 36-41. doi: 10.7619/jcmp.20241055

    LI J J, ZHANG J F, NIU H W, et al. Efficacy and safety of camrelizumab combined with tegafur, gimeracil and oteracil potassium capsule in treating advanced esophageal squamous cell carcinoma[J]. Journal of Clinical Medicine in Practice, 2024, 28(12): 36-41. doi: 10.7619/jcmp.20241055
    [20]
    刘祎, 张超, 潘炜华. 卡瑞利珠单抗引起的皮肤不良反应[J]. 临床皮肤科杂志, 2024, 53(4): 245-248.

    LIU W, ZHANG C, PAN W H, et al. Carilizumab-induced cutaneous adverse reactions[J]. J Clin Dermatol, 2024, 53(4): 245-248.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (18) PDF downloads(2) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return